[Betta Pharmaceuticals: BPI-572270 capsules have been approved by the U.S. FDA for clinical trials of new drugs] On October 7, Betta Pharmaceuticals (300558.SZ) announced that the clinical trial application for BPI-572270 capsules submitted by the company's wholly-owned subsidiary Jingyao Biotech was approved by the U.S. FDA and is intended to be used for advanced solid tumors. The drug is a self-developed pan-RAS "non-degradable molecular glue" inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on a variety of RAS mutated tumor cells. The company reminds that the research and development cycle of new drugs is long, the investment is large, and the results of clinical trials and approvals are uncertain, which will not have a significant impact on recent performance.